Aspire Biopharma faces potential Nasdaq delisting after compliance shortfall
Standex International Corp stock reached an all-time high of $219.87, marking a significant milestone for the company. According to InvestingPro data, the company shows strong financial health with a current ratio of 2.88x, indicating robust liquidity. Over the past year, the stock has experienced a notable increase of 26.07%, reflecting strong investor confidence and robust company performance. The company has maintained dividend payments for 55 consecutive years and achieved 9.64% revenue growth in the last twelve months. This achievement underscores Standex International Corp’s continued growth and resilience in the market, as it navigates economic challenges and capitalizes on emerging opportunities. The company’s strategic initiatives and operational efficiencies have likely contributed to this upward trajectory, attracting increased interest from investors and analysts alike. Based on InvestingPro’s Fair Value analysis, the stock appears to be trading above its intrinsic value, with 12 additional ProTips available for subscribers seeking deeper insights into the company’s fundamentals.
In other recent news, Standex International Corporation reported strong financial results for the fourth quarter of 2025. The company exceeded market expectations with an earnings per share (EPS) of $2.28, surpassing the forecast of $2.10, which represents an 8.57% surprise. Revenue also outperformed projections, reaching $222 million compared to the anticipated $214.44 million. Following these robust earnings, DA Davidson raised its price target for Standex International to $219, maintaining a Buy rating. The firm highlighted the potential for the company to reverse a nearly two-year trend of quarterly organic revenue declines. Similarly, Roth/MKM increased its price target to $205, also maintaining a Buy rating, citing Standex’s impressive 23% year-over-year sales growth and expanded adjusted EBITDA margins by 350 basis points. These developments suggest strong investor confidence in Standex’s future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.